Kura Oncology, Inc. (KURA)

Market Cap	1.24B
Revenue (ttm)	n/a
Net Income (ttm)	-197.55M
Shares Out	77.76M
EPS (ttm)	-2.36
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	615,467
Open	15.96
Previous Close	15.96
Day's Range	15.44 - 16.09
52-Week Range	9.06 - 24.17
Beta	0.86
Analysts	Strong Buy
Price Target	29.83 (+87.49%)
Earnings Date	Nov 7, 2024

About KURA

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpeli...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2014
• Employees: 142
• Stock Exchange: NASDAQ
• Ticker Symbol: KURA
• Website: https://kuraoncology.com

Analyst Forecast

According to 7 analysts, the average rating for KURA stock is "Strong Buy." The 12-month stock price forecast is $29.83, which is an increase of 87.49% from the latest price.

Price Target

$29.83

(87.49% upside)

Analyst Consensus: Strong Buy